Co-financing from the state budget from the Medical Research Agency
Project: FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases.
Agreement No.: 2022/ABM/05/00005
The aim of the project "FGF1 analogue: a new therapeutic target for non-alcoholic fatty liver disease and related metabolic diseases" is to bring to the market a new product based on protein therapy targeting so-called metabolic syndrome: non-alcoholic fatty liver disease (NAFLD), obesity, hypertriglyceridemia, hypercholesterolemia and hyperglycemia. The indicated therapeutic areas are important targets for modern therapies, since the incidence of the metabolic syndrome ranges from 20 to 25% in the adult population and from 0 to 19.2% in children; but can be as high as almost 80% in people with type 2 diabetes. A combination of conditions that occur together dramatically increases the risk of heart disease, stroke, and type 2 diabetes.
Co-financing value: PLN 26,999,202.96
The total cost of the project: PLN 49,940,290.61